In the wake of disappointing clinical results for an experimental breast cancer drug,...
In the wake of disappointing clinical results for an experimental breast cancer drug, Sanofi-Aventis (SNY) gets more bad news. An Australian court ruled that SNY waited too long to object to the introduction of generic forms of Taxotere, and that Hospira (HSP) and Interpharma may proceed with the introduction of their generic rivals. Taxotere makes up about 95% of Sanofi's Australian oncology business.
From other sites
at Zacks.com (Thu, 6:40PM)
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 16, 2015)
at MarketWatch.com (Feb 19, 2015)
at Benzinga.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs